This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Oncology Space Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.
LabCorp (LH) to Expand Clinical Trails Access With New Pact
by Zacks Equity Research
LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.
Bear of the Day: Becton, Dickenson and Co (BDX)
by David Bartosiak
Earnings have been retreating on this Bear of the Day.
McKesson (MCK) Up 5.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.
Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal
by Zacks Equity Research
Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.
Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall
by Zacks Equity Research
Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.
Here's What Key Metrics Tell Us About Labcorp (LH) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 2.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More
by Urmimala Biswas
Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.
Labcorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease
by Zacks Equity Research
Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
LabCorp (LH) to Expand Diagnostics Services With New Deal
by Zacks Equity Research
LabCorp's (LH) recent deal will bring together critical expertise, experience and technology from both organizations to improve the delivery of high-quality patient care.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.
Owens Corning and Labcorp have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Owens Corning and Labcorp are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Labcorp (LH)
by Derek Lewis
A slowdown in COVID-19 testing has negatively impacted the company's performance, with shares facing selling pressure post-earnings regularly in 2023.
LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes
by Zacks Equity Research
Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Labcorp (LH) Q2 Earnings Lag Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of -1.44% and 1.62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.
Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART
by Urmimala Biswas
Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.
Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sales rebound in the base business for Diagnostics business and strong drug development orders are expected to have driven LabCorp's (LH) second-quarter performance.